Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Chimeric Dengue/Zika Viruses for Live-Attenuated Zika Vaccine Development
Case ID:
TAB-3226
Web Published:
12/6/2022
Zika virus (ZIKV) can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause microcephaly and other severe birth defects. Currently, there are no vaccines to prevent or medications to treat Zika infections.
CDC engineered chimeric Zika viruses on the dengue virus (DENV) sub-type 2 (D2) PDK-53 vaccine backbone (D2 PDK-53) for potential development of a live-attenuated Zika vaccine. These chimeric viruses could also be used for other research purposes such as development of diagnostic tests. The cDNA genetic clones for the chimeric constructs have been successfully engineered, and scientists in the laboratory are in the process of deriving infectious chimeric D2 PDK-53/Zika viruses.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech?title=Chimeric_Dengue%2fZika _Viruses_for_Live-Attenuated_Zika_Vaccine_Development
Keywords:
chimeric
Dengue/Zika
Development
Live-Attenuated
NCEZID-DVBD
Vaccine
Viruses
VLXXXX
WBXXXX
WIXXXX
WNXXXX
XEXXXX
XKXXXX
YAXXXX
YBXXXX
Zika
Bookmark this page
Download as PDF
For Information, Contact:
Jeremiah Mitzelfelt
LPM
NIH Technology Transfer
301-443-8518
jeremiah.mitzelfelt@nih.gov